C&B Minicast

Can Psychedelics Change the Future of Mental Health Treatment?

Cognitive & Behavioral Health Center of Charleston Season 2 Episode 10

Send us a text

Can psychedelics change the future of mental health treatment? In this episode, we provide an overview of psychedelic research over the past five years.  Studies on psilocybin, MDMA, ketamine and esketamine are discussed.   Curious about participating in a trial? Visit ClinicalTrials.gov.

#CBHealthCharleston #MentalHealthAwareness #PsychedelicResearch #KetamineTherapy #PsilocybinHealing #MDMAWellness #ClinicalTrials


American
 Psychiatric Association. (2022). Position
 statement on the use of psychedelic and empathogenic agents for mental health conditions
.
American Psychiatric Association.
https://www.psychiatry.org/

Bogenschutz,
M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., ... & Khalsa, S. S. (2022). Percentage of heavy drinking days following psilocybin-assisted treatment for alcohol use disorder: A randomized clinical trial.
JAMA
 Psychiatry, 79
(10),
953–962.
https://doi.org/10.1001/jamapsychiatry.2022.2096

Carhart-Harris,
R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., ... & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression.
New
 England Journal of Medicine, 384
(15),
1402–1411.
https://doi.org/10.1056/NEJMoa2032994

Daly,
E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., ... & Drevets, W. C. (2019). Efficacy of esketamine nasal spray plus oral antidepressant vs antidepressant plus placebo for relapse prevention in treatment-resistant depression: A randomized clinical
trial. JAMA
 Psychiatry, 76
(9),
893–903.
https://doi.org/10.1001/jamapsychiatry.2019.1189

Goodwin,
G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... & Wiegand, F. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression.
New
 England Journal of Medicine, 387
(18),
1637–1648.
https://doi.org/10.1056/NEJMoa2206443